Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 29, 2023

Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With T2D and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir–Ritonavir During the Omicron Wave in Hong Kong

JAMA Network Open

 

Additional Info

JAMA Network Open
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong
JAMA Netw Open 2023 May 01;6(5)e2314393, DTW Lui, MSH Chung, EHY Lau, KTK Lau, ICH Au, CH Lee, YC Woo, CKH Wong, BJ Cowling

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading